Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia
ConditionAndrogenic Alopecia
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18-55
SponsorSohag University
About this trial
Evaluation of Safety and efficacy of autologous stromal vascular fraction derived from denovo versus platelet rich plasma enhanced donner site in treatment of male androgenic alopecia
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Male patients with androgenic alopecia
Disqualifiers
Patients with other hair loss disorders as telogen effluvium, anagen effluvium, alopecia areata, cicatricial alopecia and trichotillomania.
Trial design
Design model
Parallel
Treatments tested in this trial
autologous stromal vascular fraction
Procedure/Surgeryautologous stromal vascular fraction injection as 2 sessions with 1 month interval at arm 1 arm 2: will receive 2 sessions of PRP with 3 weeks interval followed by stromal vascular fraction injection as 2 sessions with 1 month interval
Treatment groups
40 Participants
are divided into 2 treatment groupsGroup A: autologous stromal vascular fraction derived from denovoActive comparator 1 intervention
Group B: autologous stromal vascular fraction after platelet rich plasma enhanced donner siteActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
hair density
Trichoscopy
Time frame
at baseline and at 6 month after treatment2
hair shaft thickness
TrichoScan
Time frame
at baseline and at 6 month after treatmentLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: